echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Up-regulation of histone deacetylase 6 is associated with the malignancy of melanoma and the prognosis of patients

    Up-regulation of histone deacetylase 6 is associated with the malignancy of melanoma and the prognosis of patients

    • Last Update: 2021-04-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Defu Medical Publishing House published a new article in the Journal of Cancer Management and Research.
    Up-regulation of histone deacetylase 6 is related to the malignant degree of melanoma and the prognosis of patients.

    Abstract Background: Melanoma is the most malignant skin tumor, and its morbidity and mortality are increasing year by year.

    In recent years, more and more researchers have devoted themselves to exploring the biological characteristics of melanoma, but there are no clinical biomarkers that can predict the occurrence and development of melanoma.

    Histone deacetylase 6 (HDAC6) has been shown to be a prognostic biomarker in a variety of cancers.

    In this study, we aimed to explore the predictive value of HDAC6 on the prognosis of patients with skin melanoma.

    Methods: 80 cases of skin melanoma patients were enrolled in this study.

    Detect the protein level and mRNA expression level of HDAC6, and analyze the relationship between the expression of HDAC6 and the clinical characteristics and survival time of patients with skin melanoma.

    Results: The results showed that the high expression of HDAC6 was significantly related to poor clinicopathological characteristics.

    The high expression of HDAC6 is associated with metastasis of melanoma, and it is also associated with a reduction in the survival time of patients with melanoma.

    Conclusion: The expression level of HDAC6 can be used as a biomarker to predict the prognosis of patients with skin melanoma.

    Keywords: HDAC6; skin melanoma; prognostic biomarkers; survival rate; metastasis
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.